UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

  

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 19, 2012

  

INTERCEPT PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

 

Delaware   001-35668   22-3868459

(state or other jurisdiction

of incorporation) 

 

(Commission

File Number) 

 

(I.R.S. Employer

Identification No.) 

 

         

18 Desbrosses Street

New York, New York  

       10013
(Address of principal executive offices)       (Zip Code)

 

Registrant’s telephone number, including area code: (646) 747-1000

 

(Former name or former address, if changed since last report)

  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

 
 

 

Item 8.01 Other Events. 

 

On December 19, 2012, Intercept Pharmaceuticals, Inc. issued a press release announcing that it has completed enrollment in POISE, its pivotal Phase 3 clinical trial of obeticholic acid (OCA) in primary biliary cirrhosis (PBC).  

 

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.

Item 9.01       Financial Statements and Exhibits.

 

(d)   The following exhibit is filed with this report:

 

Exhibit
Number		 Description
   
99.1 Press Release dated December 19, 2012.

 

The press release contains hypertext links to information on our website and/or other websites.  The information contained in or accessible from our website or any other website is not incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Form 8-K.

 

 

   

 
 

  

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

         
        INTERCEPT PHARMACEUTICALS, INC.
     
Date: December 19, 2012       /s/ Mark Pruzanski
       

Mark Pruzanski, M.D.

President and Chief Executive Officer